CASE REPORT

Autoimmune glial fibrillary acidic protein astrocytopathy manifesting as subacute meningoencephalitis with descending myelitis: a case report

Han Wang1*, Jerome H. Chin2†, Bo-yan Fang3, Xi Chen1,4, Ai-lin Zhao5, Hai-tao Ren1 and Hong-zhi Guan1

Abstract

Background: Glial fibrillary acidic protein (GFAP) autoimmune astrocytopathy is characterized by GFAP autoantibody positive encephalitis, meningoencephalitis or meningoencephalomyelitis. The initial clinical presentation may be similar to central nervous system infections making early diagnosis challenging.

Case presentation: A Chinese female patient presented with subacute meningitis with symptoms of headache, vomiting, and fever. Cerebrospinal fluid (CSF) analysis showed monocytic pleocytosis, elevated protein level, low glucose level, and negative basic microbiological studies including Xpert MTB/RIF. Brain magnetic resonance imaging (MRI) showed bilateral cerebral cortical and white matter hyperintensities on FLAIR sequences. The patient was diagnosed with possible tuberculous meningitis and started on anti-tuberculosis therapy (ATT). Three months later, the patient developed cervical myelopathy and encephalopathy with persistent CSF pleocytosis. Five months later, tissue-based and cell-based assays demonstrated GFAP antibodies in blood and CSF. Her symptoms improved with repeated administration of intravenous immunoglobulin (IVIG) and corticosteroids. One-and-a-half -year follow-up showed neither clinical progression nor relapses.

Conclusions: Anti-GFAP astrocytopathy should be included in the differential diagnosis of patients who present with subacute meningitis with negative microbiological studies and a progressive clinical course including encephalitis and/or myelitis.

Keywords: GFAP, Encephalitis, Meningitis, Myelitis, Autoimmune

Background

Autoimmune astrocytopathy with antibodies to glial fibrillary acidic protein (GFAP) was first described in 2016 [1]. The predominant clinical syndrome is meningoencephalomyelitis or a limited form of the same, i.e. meningitis, encephalitis, and/or myelitis [1–7].

* Correspondence: wanghanpumch@163.com
† Han Wang and Jerome H. Chin are authors contributed equally to the manuscript
1 Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
tuberculosis for 9 months prior to the diagnosis of anti-GFAP astrocytopathy with clinical involvement of brain and spinal cord documented by neuroimaging.

**Case presentation**

A 28-year-old female was admitted with fever (39.4 °C), headache, vomiting, and cough for 1 week. Medical history was notable for chronic hepatitis B. Chest CT was normal. Brain MRI showed hyperintensities on T2 FLAIR sequences in bilateral cortical and subcortical regions (Fig. 1). No abnormal enhancement or hydrocephalus was seen. Cerebrospinal fluid (CSF) analysis showed glucose 2.52 mmol/L, protein 1.76 g/L, and white blood cells 300 × 10^6/L (80% mononuclear cells). Acid fast stain, India Ink preparation, and bacterial culture were negative. She experienced one convulsion. Gancyclovir was administered for 3 days. Possible tuberculous meningitis was diagnosed and anti-tuberculosis therapy (ATT) was started with oral rifampicin, pyrazinamide, and ethambutol. Isoniazid and dexamethasone were administered intrathecally every 2–6 days for 1 month. CSF was sampled six times during intrathecal treatments and showed persistent pleocytosis with white blood cells of 80 to 394 cells × 10^6/L (80–90% mononuclear cells). Ethambutol was withdrawn due to blurred vision and replaced with levofloxacin. Her fever and headaches improved but tremor developed in both hands.

Three months later, she developed back pain, leg weakness, memory loss, irritability, and confusion. These symptoms progressed and eventually she could not walk independently. Cervical MRI demonstrated patchy hyperintensities in the spinal cord extending from C2-C7 (Fig. 2). Brain MRI demonstrated linear and radial gadolinium enhancement extending perpendicular to the lateral ventricles (Figs. 3 and 4). CSF analysis showed glucose 2.32 mmol/L, protein 1.09 g/L, and white blood cells 52 × 10^6/L (90% mononuclear cells). Testing of CSF for *Mycobacterium tuberculosis* (MTB) by nucleic acid amplification testing (Xpert MTB/RIF) and culture (MGIT) were both negative. ATT was adjusted to moxifloxacin, amikacin, isoniazid, rifampicin, and pyrazinamide. Intravenous
immunoglobulin (IVIG) was administered (25 g/day × 5 days) with improvement of her symptoms. Methylprednisolone was given intravenously (1 g/day × 3 days, 500 mg/day × 3 days) without further improvement.

She was referred to our hospital 5 months later. She had weakness of the right leg, hyperactive deep tendon reflexes, bilateral Babinski signs, unsteady gait, limb incoordination, and hand tremor. ATT consisted of rifampicin, pyrazinamide, and moxifloxacin. CSF analysis showed glucose 2.7 mmol/L, protein 0.89 g/L, white blood cells 14 × 10⁶/L (86% mononuclear cells), and positive oligoclonal bands. Blood tests for TSH, Free T4, T3, B12, ESR, CRP were normal. Serum tests for infection including HIV 1/2 antibody, HSV1 IgM, HSV2 IgM and IgG, CMV IgM, EBV DNA, HCV, cryptococcal antigen, and TPPA were negative. Tests for autoimmune disease (ANA, anti-DS DNA, anti-RNP, anti-SSA/SSB, anti-Scl-70, anti-Jo-1, anti-Sm, ANCA, anti-TPO) and neoplasm (CA 242, SCC Ag, AFP, CEA, CA19–9, CA125, CA72–4, CA15–3, Cyfra 21–1) were negative. The following serum autoimmune encephalitis antibodies were negative: Hu, Yo, Ri, Amphiphysin, Ma2/Ta, CV2/CRMP5, AQP4, NMDA, AMPA1, AMPA2, GABAB, CASPR2, LGI1, GAD65.

After reviewing of the brain MRI studies from the referring hospital, the linear perivascular radial gadolinium enhancement patterns (Figs. 3 and 4) made us suspect anti-GFAP astrocyopathy. Tissue-based and cell-based assays for GFAP antibodies were sequentially tested and antibodies were detected in blood and CSF. The GFAP antibody titers in serum and CSF were 1:32 and 1:100 respectively (Fig. 5). Repeat brain MRI revealed persistent but subtle radial periventricular enhancement (image not shown). IVIG (25 g/day × 5 days) and prednisone (30 mg daily) were administered. Her leg weakness improved and she could ambulate without assistance at discharge. Prednisone was continued and tapered over 6 months. She has been followed for one and a half year without progression or relapses.

**Discussion and conclusions**

Anti-GFAP astrocyopathy is an autoimmune disorder with a broad spectrum of neurological presentations [1–5]. Fever, headache, and meningeal symptoms are frequently reported as initial symptoms and some patients have prodromal influenza-like symptoms. This has raised speculation that certain cases of autoimmune GFAP astrocyopathy may be induced by an antecedent viral or bacterial infection. Our patient was diagnosed with tuberculous meningitis without microbiological confirmation and treated with ATT and dexamethasone. Her early symptoms improved but she developed new and progressive neurological symptoms including cognitive and motor deficits. CSF analyses demonstrated persistent pleocytosis and elevated protein levels for 9 months which has not been previously reported to our knowledge in patients with anti-GFAP astrocyopathy. In a case series of fourteen patients in Japan, CSF pleocytosis was detected in one patient up to 6 months [3].

Patients with subacute meningitis and negative routine microbiological studies of CSF for non-mycobacterial bacteria and fungi are often treated empirically with ATT since no microbiological test including cultures can rule out tuberculous meningitis [8]. Kimura et al. [3] reported five of fourteen patients with anti-GFAP
astrocytopathy who were initially diagnosed with tuberculosis meningitis and treated with ATT. Iorio et al. [4] described one patient that was initially diagnosed with tuberculous meningitis. All of these cases had negative polymerase chain reaction testing and culture for MTB from CSF specimens. Notably, Kimura et al. [3] reported transient elevations of adenosine deaminase (ADA; cutoff value 10 IU/L) in the CSF of most of their patients with anti-GFAP astrocytopathy. ADA is a non-specific biomarker that can be elevated in tuberculous meningitis [8]. We did not measure ADA levels in the CSF of our patient.

The differential diagnosis of meningoencephalomyelitis is broad and includes infectious, post-infectious, and autoimmune diseases of the central nervous system. Coexisting neural autoantibodies have been reported in some patients with anti-GFAP astrocytopathy including antibodies to NMDA receptors, GABA-A receptors, and aquaporin-4 [2–4]. Brain and cervical MRI studies in our patient demonstrated abnormalities reported in cases of anti-GFAP astrocytopathy [7] which led to our search for and discovery of antibodies to GFAP in the blood and CSF. Although not specific for autoimmune encephalitis [2], linear perivascular radial gadolinium enhancement extending outwards from the lateral ventricles was seen in our patient and has been reported in case series of patients with anti-GFAP astrocytopathy from the U.S. [2], Japan [3], and China [5] at frequencies of 53, 28.6, and 42.1%, respectively. Long et al. [5] described longitudinally extensive spinal cord lesions on MRI in 11 out of 16 patients and we found similar findings in our patient.

Acute treatments for anti-GFAP astrocytopathy include intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIG), intravenous dexamethasone, and plasma exchange with variable responses [2–5]. Three groups [2–4] reported improvements in most of their patients with immunotherapy whereas Long et al. [5] stated, “Most of our patients did not respond very well to routine IVMP and IVIG therapy during the acute stage or long-term treatment with oral steroids and immunosuppressants”. Our patient improved after two separate courses of IVIG. She received one course of IVMP after the first course of IVIG without additional benefit over her positive response to IVIG.

In summary, anti-GFAP astrocytopathy should be considered in the differential diagnosis for patients who present with subacute meningitis and negative microbiological studies for bacteria, mycobacteria, fungi and viruses. A worsening and/or progressive neurological course, including symptoms and signs of encephalopathy and myelopathy, and persistent CSF pleocytosis despite antimicrobial therapy, e.g. ATT, should prompt testing.
for anti-GFAP antibodies and other neural autoantibodies which may coexist. Whether infections including tuberculous meningitis could have a pathogenic role in the development of anti-GFAP astrocytopathy in certain cases requires further research. Although consensus treatment guidelines are not available, IVMP, IVIG, and plasma exchange may produce improvement in some, but not all patients.

**Abbreviations**
GFAP: Glial fibrillary acidic protein; ATT: Anti-tuberculosis therapy; CSF: Cerebrospinal fluid; MTB: Mycobacterium tuberculosis; MRI: Magnetic resonance imaging; IVMP: Intravenous methylprednisolone; IVIG: Intravenous immunoglobulin

**Acknowledgements**
We thank Lei Liu for the GFAP examination and Professor Jing Gao for her advice on the treatment of this patient in the regular rounds.

**Authors’ contributions**
HW and JC designed and conceptualized study, analyzed and interpreted the patient data, drafted the manuscript for intellectual content. BYF and HTR organized the immunologic examination of the blood and CSF, BYF was also a major contributor in writing the manuscript. XC and ALZ acquired and analyzed the clinical data, ALZ drafted the manuscript. HZG followed up the patient. All authors read and approved the final manuscript.

**Authors’ information**
Not applicable.

**Funding**
The work was supported by Beijing Natural Science Foundation (7182077) and National Natural Science Foundation of China (81870950) from Boyan Fang. The funding body had no role in the protocol design, the statistical analysis and the manuscript preparation.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**
This study was approved by the Institutional Review Board of PUMCH.

**Consent for publication**
Written informed consent for patient information and images to be published was provided by the patient.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. 2Department of Neurology, NYU Langone Health, New York, NY, USA. 3Department of Neurology, Beijing Rehabilitation Hospital Affiliated to Capital Medical University, Beijing, China. 4Department of Neurology, Tonghua Central Hospital, Jilin, China. 5Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Received: 26 August 2020 Accepted: 2 December 2020
Published online: 10 December 2020

**References**
1. Fang B, McKeon A, Hinson SR et al. Autoimmune glial fibrillary acidic protein Astrocytopathy: A Novel Meningoencephalomyelitis JAMA Neurol 2016; 73:1297–1307.
2. Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein ImmunoglobulinG as biomarker of autoimmune Astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81:298–309.
3. Kimura A, Takekoshi A, Yoshikura N, Hayashi Y, Shimohata T. Clinical characteristics of autoimmune GFAP astrocytopathy. J Neuroimmunol. 2019;329:1–8.
4. Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry. 2018;89:138–46.
5. Long Y, Liang J, Xu H, et al. Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study. Eur J Neurol. 2018; 25:477–83.
6. Shan F, Long Y, Qiu W. Autoimmune glial fibrillary acidic protein Astrocytopathy: a review of the literature. Front Immunol. 2018;9:2802.
7. Zekeidou A, McKeon E, P. Flanagan. A path to understanding autoimmune GFAP astrocytopathy. Eur J Neurol. 2018;25:421–2.
8. Chin JH. Neurotuberculosis: a clinical review. Semin Neurol. 2019;39:456–61.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.